Dr. Pradipta Ghosh has established a new paradigm in signal transduction by characterizing a new family of guanine-nucleotide exchange factors (GEFs) which allow diverse receptors, not just GPCRs, to transactivate heterotrimeric G-proteins. She unraveled the molecular mechanisms that govern such activation and established its unique spatio-temporal features. Finally, she demonstrated the relevance of this paradigm to modern medicine by defining the therapeutic potential of key signaling interfaces in diverse pathophysiologic states including diabetes, organ fibrosis, and cancer. Going forward, her group uses a combination of biochemical, cell biological and translational model systems, including, but not limited to protein chemistry, computational modeling, systems biology, mathematical modeling and bioinformatics approaches to unravel the complexities of how a variety of receptors communicate with the newly discovered family of GEFs, and what are the functional consequences of such interactions. Once systematically applied, these approaches have the real potential to revolutionize our understanding of signal transduction and the diverse biological processes and disease states that they control.